The National Institute for Health and Care Excellence

New AI tools could help spot prostate cancer more accurately

Innovative AI technologies have the potential to act like a ‘second pair of eyes’, helping radiologists review prostate MRI scans.
National Institute for Health and Care Excellence

News, blogs and podcasts

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use. People with obsessive-compulsive disorder (OCD) and body dysmorphic ...
National Institute for Health and Care Excellence

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It ...
National Institute for Health and Care Excellence

Prostate cancer

All NICE products on prostate cancer. Includes any guidance, advice and quality standards.
National Institute for Health and Care Excellence

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...
National Institute for Health and Care Excellence

Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia

There is a simple discount patient access scheme for quizartinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...
National Institute for Health and Care Excellence

Tirzepatide for managing overweight and obesity

A commercial access agreement was added to this guidance and the price list for tirzepatide was updated. Next review: This guidance will be reviewed if there is new evidence that is likely to change ...
National Institute for Health and Care Excellence

BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups

This guidance has been updated and replaced by obesity: identification, assessment and management ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
National Institute for Health and Care Excellence

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...